Hexarelin

Mechanism of Action

Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) that binds to and activates the growth hormone secretagogue receptor (GHS-R1a), stimulating growth hormone release from the pituitary gland via a Gq-coupled signaling pathway that increases intracellular calcium. Additionally, hexarelin binds to the CD36 scavenger receptor, which mediates distinct cardiovascular and metabolic effects independent of GH release, including activation of PPARgamma pathways that regulate cholesterol metabolism. Key Pathways: GHS-R1a receptor activation → Gq signaling → increased intracellular calcium → GH release, CD36 scavenger receptor binding → PPARgamma activation → cholesterol efflux regulation, Akt/GSK-3β phosphorylation pathway → anti-apoptotic/neuroprotective effects The GHS-R1a activation drives growth hormone release, which theoretically supports muscle growth and fat metabolism. The cardioprotective effects observed in heart failure models appear mediated through both GH-dependent and GH-independent pathways, including reduced cardiomyocyte apoptosis and improved ventricular function. Neuroprotective effects seen in animal models involve Akt pathway activation and reduced caspase-3 activity.

Common Dose Reference Ranges

Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.

Full Hexarelin protocols — frequency, timing, cycle length, reconstitution & research